Autonomix Medical, Inc. announced on August 14, 2025, that it has advanced its proprietary sensing catheter through a final design review. This crucial step prepares the device for human clinical trials in the United States.
The innovative sensing catheter is the first intravascular device of its kind engineered to detect and differentiate nerve signals in real time from inside the vasculature, utilizing Autonomix's proprietary microchip-based sensing antenna array. This technology aims to provide a 'sense, treat, and verify' approach, allowing physicians to precisely locate target nerves, guide energy delivery, and confirm ablation efficacy during procedures.
CEO Brad Hauser highlighted that completing this design review reinforces the strength of their development program and brings the company closer to delivering safer, more effective treatment options. This milestone is a major step towards submitting an Investigational Device Exemption (IDE) and commencing U.S. clinical trials to support a De Novo FDA application for pancreatic cancer pain treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.